Highlights of This Issue  807

CELL DEATH AND SURVIVAL

809  HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer
Haifeng Zhu, Zuzana Berkova, Rohit Mathur, Lalit Sehgal, Tamer Khashab, Rong-Hua Tao, Xue Ao, Lei Feng, Anita L. Sabichi, Boris Blechacz, Asif Rashid, and Felipe Samaniego

819  Variants of Osteoprogerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies
Jerome T. Higgs, John S. Jarboe, Joo Hyoung Lee, Diptiman Chanda, Carnellia M. Lee, Champion Deivanayagam, and Selvarangan Ponnazhagan

CHROMATIN, GENE, AND RNA REGULATION

828  The IncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus
Kouhei Sakurai, Brian J. Reon, Jordan Anaya, and Anindya Dutta

839  LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia
Thilini R. Fernando, Norma I. Rodriguez-Malave, Ella V. Waters, Weihong Yan, David Casero, Giuseppe Basso, Martina Pigazzi, and Dinesh S. Rao

DNA DAMAGE AND REPAIR

852  Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins
Uday Bhanu Maachani, Tamalee Kramp, Ryan Hanson, Shuping Zhao, Orieta Celiku, Ulma Shankavaram, Riccardo Colombo, Natasha J. Caplen, Kevin Camphausen, and Anita Tandle

GENOMICS

863  Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method
Johannes von Burstin, Sandra Diersch, Günter Schneider, Maximilian Reichert, Anil K. Rustgi, and Roland M. Schmid

870  Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome
Leiping Fu, Denise R. Minton, Tuo Zhang, David M. Nanus, and Lorraine J. Gudas

ONCOGENES AND TUMOR SUPPRESSORS

879  Tumor Suppressor NF2 Blocks Cellular Migration by Inhibiting Ectodomain Cleavage of CD44
Monika Hartmann, Liseth M. Parra, Anne Ruschel, Sandra Böhme, Yong Li, Helen Morrison, Andreas Herrlich, and Peter Herrlich

891  Breast Cancer–Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments
Nicole Guzman, Kitty Agarwal, Dilip Asthagiri, Lianbo Yu, Motoyasu Saji, Matthew D. Ringel, and Michael E. Paulaitis

902  The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells
Perla El-Hage, Ambre Petitalot, Anne-Hélène Monsoro-Burq, Frédérique Maczkowiak, Kelouma Driouch, Etienne Formstecher, Jacques Camonis, Michele Sabbah, Ivan Bikche, Rosette Lidereau, and François Lallemand

913  The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DPYRK1B Kinase
Liang-Nian Song, Jose Silva, Antonius Koller, Andrew Rosenthal, Emily I. Chen, and Edward P. Gelmann
Table of Contents

SIGNAL TRANSDUCTION

923 mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer
Valerie L. Sodi, Sakina Khaku, Raisa Krutilina, Luciana P. Schwab, David J. Vocadlo, Tiffany N. Seagroves, and Mauricio J. Reginato

934 MAPK7 Regulates EMT Features and Modulates the Generation of CTCs
Sarah Javaid, Jianmin Zhang, Gromoslaw A. Smolen, Min Yu, Ben S. Wittner, Anurag Singh, Kshitij S. Arora, Marissa W. Madden, Rushil Desai, Matthew J. Zubrowski, Benjamin J. Schott, David T. Ting, Shannon L. Stott, Mehmet Toner, Shyamala Maheswaran, Toshi Shioida, Sridhar Ramaswamy, and Daniel A. Haber

ABOUT THE COVER
Epithelial-to-mesenchymal transition (EMT) has been implicated in tumor cell migration, invasion, and metastasis. Suppression of MAPK7 increases E-cadherin (CDH1) expression, inhibits cell migration, and reduces circulating tumor cells and the appearance of lung metastases. The cover shows immunofluorescent staining of A549 cancer cells following knockdown of MAPK7, showing increased expression of CDH1 localized to the cell membrane (CDH1, green, Vimentin, red, DAPI, blue). Please see the article by Javaid and colleagues (beginning on page 934) for more information.